Abbvie Inc. vs Halozyme Therapeutics, Inc.
ABBV vs HALO — side-by-side comparison from reported financials. ABBV leads 3, HALO leads 6 of 9 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Halozyme Therapeutics, Inc.
HALO · Healthcare
$111.35+1.38%Mixed
| Metric | ABBV | HALO |
|---|---|---|
| Price | $276.43 | $111.35 |
| Market cap | $488B | $12.6B |
| Revenue (TTM) | $64.4B | $1.66B |
| Revenue growth | +1.8% | +28.4% |
| Net margin | 9.8% | 24.9% |
| Free cash flow | $18.2B | $806M |
| Net cash (debt) | ($56.2B) | ($2.01B) |
| 1-year price return | +19.8% | +71.0% |
| P/E | 77.4 | 30.3 |
| P/E vs own history (cheap-side %) | 23% | 8% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 181% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 423 |
Full résumé-style profiles: ABBV CV · HALO CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.